Wire · opportunities
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
Eli Lilly announced a 79.3% response rate in a phase 1 trial of their antibody-drug conjugate Sofe-M for platinum-sensitive ovarian cancer, competing with AbbVie and Genmab in this market. The trial showed consistent efficacy across patient subgroups and tolerable safety, supporting Lilly's ongoing phase 3 FRAmework-01 trial.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face rising competition in platinum-sensitive ovarian cancer where early clinical success now hinges on first-mover advantage for topoisomerase inhibitor ADCs. Acting fast to establish market presence or differentiate your ADC payload could secure your lead before resistance and rivalry narrow options.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics